A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
Saverio D’Amico(Humanitas University), Matteo Della Porta(Humanitas University), Elisabetta Sauta(Humanitas University), Rami S. Komrokji(Moffitt Cancer Center), Marilena Bicchieri(Istituti di Ricovero e Cura a Carattere Scientifico), Victor Savevski(Humanitas University), Matteo Franchi(University of Milano-Bicocca), Alessia Campagna(Humanitas University), Matteo Zampini(Humanitas University), Fabio Efficace(Fondazione Gimema Onlus), Gastone Castellani(University of Bologna), Alberto Zambelli, Alberto Porta(University of Milan), Matteo Brindisi(IRCCS Humanitas Research Hospital), Torsten Haferlach(Munich Leukemia Laboratory (Germany)), Cristina Astrid Tentori(IRCCS Humanitas Research Hospital), Shahram Kordasti(Guy's Hospital), Gabriele Todisco(Humanitas University), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Amer M. Zeidan(Yale Cancer Center), Marta Ubezio(Humanitas University), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Flavia Jacobs(IRCCS Humanitas Research Hospital), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Laura Crisafulli(Humanitas University), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Lorenzo Dall'Olio(University of Bologna), Valeria Santini(University of Florence), Gianluca Asti(IRCCS Humanitas Research Hospital), Alessandro Buizza(IRCCS Humanitas Research Hospital), Elena Zazzetti(IRCCS Humanitas Research Hospital), Mattia Delleani(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Antonio Russo(Humanitas University), Pierre Fenaux(Université Paris Cité), Elena Riva(Humanitas University), Nicole Pinocchio(IRCCS Humanitas Research Hospital), Francesca Ficara(Humanitas University)
Cited by 5
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821